Cleveland Diagnostics

Name: Cleveland Diagnostics
Address: Cleveland, OH, US
Telephone: +12164322700
Price range: $

Home
United States
Cleveland, OH
Cleveland Diagnostics

Cleveland Diagnostics offers novel, more accurate testing for early detection of cancer and risk of high-grade disease.

06/16/2026

June is National Men’s Health Month, making it a great time to talk with your doctor about prostate cancer screening.

One in eight men will be diagnosed with prostate cancer during their lifetime, and many experience no symptoms in the early stages of the disease. The good news is that prostate cancer is highly treatable when detected early.

For many men, PSA testing is an important first step in screening and is typically recommended beginning around ages 45–50, depending on family history and other risk factors.

Men should also know that an elevated PSA result is common and does not necessarily mean cancer is present. In those situations, the IsoPSA Test can provide additional insight into a patient’s risk of clinically significant prostate cancer, helping men and their physicians make more informed decisions about next steps.

Learn more: https://hubs.la/Q04lrBVh0

05/26/2026

Dr. Arnon Chait, Chief Innovation Officer at Cleveland Diagnostics, and Dr. Russ Lebovitz, Chief Executive Officer and Cofounder of Amprion, recently sat down with The Pathologist to discuss “The Chronic Disease Conundrum” and how advancing diagnostics can support our aging population.

Drs. Chait and Lebovitz agree that diagnostics need to be clinically actionable and more biology-driven, using biomarkers and proteomics to identify disease earlier and more accurately.

“Clinically actionable diagnostics must go beyond identifying abnormalities—they need to inform clinical decisions. This means delivering results that are disease- and patient-specific, reproducible, and practical within routine workflows,” Dr. Chait shares.

Read Drs. Chait and Lebovitz’s thoughts here: https://hubs.la/Q04hxsrW0

05/21/2026

In this OncLive interview, Dr. Jason Hafron with the Michigan Institute of Urology shares key takeaways from , including discussion around PC360, a quality initiative designed to support men receiving ADT for prostate cancer.

Advancing prostate cancer care requires accurate detection to support informed decision-making and improved outcomes throughout the patient journey. The IsoPSA Test is designed to help support risk stratification and biopsy decision-making as part of that broader continuum of care.

05/18/2026

Thank you for another incredible meeting, American Urological Association! We enjoyed connecting with urologists and thought leaders and exploring the latest research shaping prostate cancer risk assessment at .

We look forward to joining you next year in San Diego!

05/17/2026

As conversations at continue to expand how we think about cancer detection, one theme has emerged: while finding more cancer is valuable, we still need increased focus on identifying clinically significant disease.

This article from AUA News highlights the growing concern around overdiagnosis and overtreatment. The IsoPSA Test was designed to address that challenge: improving detection of clinically significant prostate cancer while simultaneously helping reduce unnecessary biopsies and overtreatment of indolent disease.

Read the article here: https://hubs.la/Q04gVrcs0

05/16/2026

Live from : There’s still time to visit the team at booth #4111!

Stop by to learn how the IsoPSA Test can support more informed prostate biopsy decisions through more accurate risk stratification.

05/15/2026

Greetings from ! Our team has arrived in Washington, DC, and we are looking forward to connecting with the urology community.

Visit us at booth #4111 to discuss the evolving landscape of prostate cancer detection and learn how the IsoPSA Test can support more confident risk stratification and biopsy decision-making.

05/05/2026

Join us at AUA 2026 in Washington, DC, and visit our booth ( #4111) to connect with our team.

As you know, PSA is a valuable screening tool, but it lacks specificity. The results may not allow clinicians to distinguish clinically significant prostate cancer (csPCa) from benign conditions like prostatitis, inflammation, or BPH.

The IsoPSA Test is different. It’s designed to improve specificity, enhance MRI results, and provide insight into a patient’s risk of csPCa over the next 30 months.

To learn more, stop by booth #4111 or go to https://hubs.la/Q04c9tPP0.

04/29/2026

A recent article highlights ongoing efforts to reduce unnecessary prostate biopsies through improved risk stratification.

The IsoPSA Test was developed to address the limitations of PSA by improving specificity for clinically significant prostate cancer. In clinical use, the IsoPSA Test has demonstrated the ability to reduce biopsy recommendations for low-risk patients while also helping to identify high-risk patients for intervention or closer monitoring.

Read the article to learn more about how diagnostic advancements like the IsoPSA Test can support the detection of clinically significant disease while also helping avoid cases of overtreatment: https://hubs.la/Q04c8sbv0

04/23/2026

This Medical Laboratory Professionals Week , we are celebrating and recognizing the critical role our laboratory team plays in delivering diagnostic insights to patients and clinicians nationwide.

Their expertise and commitment to excellence ensure that every test result is reliable and accurate.

Thank you to our lab team for the vital work you do every day to support better patient care!

Address

Cleveland, OH

Telephone

+12164322700

Website

http://www.clevelanddx.com/

Alerts

Be the first to know and let us send you an email when Cleveland Diagnostics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Cleveland Diagnostics:

Shortcuts

Want your business to be the top-listed Business in Cleveland?